14 Best Long Term Growth Stocks to Buy Now

11. Insulet Corporation (NASDAQ:PODD)

5-year EPS Growth: ~62.9%

Projected 5-year EPS Growth: ~66.3%

Number of Hedge Fund Holders: 53

Insulet Corporation (NASDAQ:PODD) is one of the Best Long Term Growth Stocks to Buy Now. On September 17, Truist Securities analyst Richard Newitter reiterated a “Buy” rating on the company’s stock with the price objective of $365.00. Insulet Corporation (NASDAQ:PODD)’s management reiterated the robust worldwide operating momentum, expecting to surpass its Q3 2025 revenue growth guidance, supported by the robust new customer starts throughout both the US and international markets. Notably, for Q3 2025, the company expects revenue growth of 22%-25%.

Insulet Corporation (NASDAQ:PODD)’s results in Q2 2025 demonstrate its attractive position as the differentiated durable-growth company amidst a large underpenetrated market. The company saw revenue of $649.1 million, reflecting a rise of 32.9%, or 31.3% in constant currency, surpassing the high end of its guidance range of 26.0% in constant currency. Insulet Corporation (NASDAQ:PODD)’s total Omnipod revenue came in at $639.0 million, up by 33.0%, or 31.4% in constant currency. The company’s US revenue rose 28.7%, above the high end of its guidance range, backed by the strong performance from its commercial team, as there was a healthy demand and momentum for Omnipod 5, which continues to drive growth in the customer base.

ClearBridge Investments, an investment management company, released its Q2 2025 investor letter. Here is what the fund said:

“Our health care exposure was a particular standout in a quarter that saw the sector overall struggle due to tariff fears and challenges in the Medicare Advantage market. Insulet Corporation (NASDAQ:PODD), a developer of insulin pumps for the treatment of diabetes, which was already seeing robust margin growth, is benefiting from Omnipod sales among the type 2 diabetes population, a market it received FDA approval for last summer.”